Brokerages Anticipate Natus Medical Incorporated (BABY) Will Post Earnings of $0.71 Per Share
Brokerages expect Natus Medical Incorporated (NASDAQ:BABY) to post earnings of $0.71 per share for the current quarter, Zacks reports. Two analysts have provided estimates for Natus Medical’s earnings. The highest EPS estimate is $0.71 and the lowest is $0.70. Natus Medical reported earnings per share of $0.51 in the same quarter last year, which indicates a positive year over year growth rate of 39.2%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, February 7th.
On average, analysts expect that Natus Medical will report full year earnings of $1.74 per share for the current financial year, with EPS estimates ranging from $1.73 to $1.74. For the next fiscal year, analysts forecast that the business will post earnings of $2.11 per share, with EPS estimates ranging from $2.08 to $2.14. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Natus Medical.
Natus Medical (NASDAQ:BABY) last announced its earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.02. The firm had revenue of $122.60 million for the quarter, compared to analysts’ expectations of $122.41 million. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. Natus Medical’s quarterly revenue was up 34.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.39 EPS.
A number of research analysts recently weighed in on BABY shares. Zacks Investment Research upgraded Natus Medical from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. BidaskClub lowered Natus Medical from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 24th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $46.50.
COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate Natus Medical Incorporated (BABY) Will Post Earnings of $0.71 Per Share” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/brokerages-anticipate-natus-medical-incorporated-baby-will-post-earnings-of-0-71-per-share/1698820.html.
Natus Medical (NASDAQ BABY) traded down $1.10 during mid-day trading on Friday, hitting $41.40. The stock had a trading volume of 299,100 shares, compared to its average volume of 359,749. Natus Medical has a 1-year low of $31.65 and a 1-year high of $43.85. The firm has a market capitalization of $1,289.78, a PE ratio of 26.71 and a beta of 0.89. The company has a quick ratio of 3.36, a current ratio of 4.21 and a debt-to-equity ratio of 0.36.
In other news, Director Robert A. Gunst sold 4,400 shares of Natus Medical stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $35.17, for a total transaction of $154,748.00. Following the sale, the director now directly owns 50,850 shares of the company’s stock, valued at $1,788,394.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director William M. Moore sold 3,000 shares of Natus Medical stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $34.10, for a total value of $102,300.00. Following the sale, the director now directly owns 30,410 shares in the company, valued at $1,036,981. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 20,042 shares of company stock worth $799,516. Corporate insiders own 5.50% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of Natus Medical by 0.6% during the second quarter. BlackRock Inc. now owns 4,149,535 shares of the medical equipment provider’s stock worth $154,779,000 after acquiring an additional 25,340 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Natus Medical by 2.9% during the second quarter. Vanguard Group Inc. now owns 2,341,546 shares of the medical equipment provider’s stock worth $87,340,000 after acquiring an additional 66,676 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Natus Medical by 10.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,552,938 shares of the medical equipment provider’s stock worth $57,924,000 after acquiring an additional 151,372 shares during the last quarter. Daruma Capital Management LLC increased its position in shares of Natus Medical by 13.1% during the second quarter. Daruma Capital Management LLC now owns 1,470,839 shares of the medical equipment provider’s stock worth $54,862,000 after acquiring an additional 169,890 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Natus Medical by 9.7% during the second quarter. Bank of New York Mellon Corp now owns 973,346 shares of the medical equipment provider’s stock worth $36,307,000 after acquiring an additional 86,192 shares during the last quarter. 94.49% of the stock is currently owned by institutional investors and hedge funds.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.